Catalog No.
YHD08201
Expression system
E. coli
Species
Homo sapiens (Human)
Protein length
Asn500-His766
Predicted molecular weight
32.65 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
P15056
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
BRAF1, RAFB1, Proto-oncogene B-Raf, BRAF, v-Raf murine sarcoma viral oncogene homolog B1, p94, Serine/threonine-protein kinase B-raf
Retrospective stratified analysis of resistance mechanisms to anti-EGFR therapy in mCRC using tumor tissue samples., PMID:40467730
[Clinical analysis of 72 children with Langerhans cell histiocytosis]., PMID:40462428
A comprehensive, multi-center, immunogenomic analysis of melanoma brain metastases., PMID:40457397
Impact of Drug-Drug Interactions on Clinical Outcomes in Metastatic Melanoma Patients Treated With Combined BRAF/MEK Inhibitors: A Real-World Study., PMID:40451782
Deciphering the role of Hashimoto's Thyroiditis-related key genes in thyroid cancer via detailed in silico analysis followed by the experimental validation., PMID:40450370
Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced melanoma with BRAFV600E or BRAFV600K mutations (EBIN): an international, open-label, randomised, controlled, phase 2 study., PMID:40449497
[Melanoma of the maxillary sinus mucosa]., PMID:40445056
BRAF oncogenic mutants evade autoinhibition through a common mechanism., PMID:40440367
In Silico Analysis of Novel circRNA-miRNA-mRNA Axis in BRAFV600E Melanoma: Implications for Primary to Metastasis Transformation and TIME Modulation., PMID:40436810
Acyclic Retinoid Overcomes Vemurafenib Resistance in Melanoma Cells via Dual Inhibition of MAPK and PI3K/AKT/mTOR Pathways., PMID:40425334
Using liquid biopsies to guide treatment and monitor response in BRAF V600E positive adenocarcinoma of unknown primary., PMID:40425210
Usefulness of CD56, BRAF and CD15 in the differential diagnosis of thyroid lesions with nuclear features of papillary carcinoma., PMID:40424929
Liquid biopsy for the detection of H3K27m in patients with brainstem tumors., PMID:40415124
miR-196b strictly regulates and reliably predicts the response to cetuximab in colorectal cancer., PMID:40414859
Encapsulated thyroid neoplasms with nuclear features of papillary carcinoma: Histological and molecular evidence that subtypes with variable extension of papillary formation may still behave favorably., PMID:40412025
Efficacy of encorafenib plus binimetinib in patients with BRAF-mutated melanoma brain metastases: Results from the Dutch Melanoma Treatment Registry., PMID:40411977
Comprehensive transcriptomic profiling of fusions and abnormal variant transcripts in pilocytic astrocytoma using NanoString nCounter technology., PMID:40403356
[Adjuvant treatment for melanoma]., PMID:40402230
Associations between pathological features and radioactive iodine-refractory recurrent papillary thyroid carcinoma: with mutation analysis using recurrent samples., PMID:40394531
[A case of pituitary involvement in pediatric multifocal craniofacial Langerhans cell histiocytosis]., PMID:40393765
Reimagining the Therapeutic Approach for Anaplastic Thyroid Cancer: The Roadmap to a Cure., PMID:40388579
Sensitivity to immune checkpoint inhibitors in BRAF/MEK inhibitor refractory melanoma., PMID:40379272
Response to a novel type II RAF inhibitor in diffuse leptomeningeal glioneuronal tumor with BRAF fusion., PMID:40377441
Concurrent Coprimary KIT Exon 17 and BRAF Mutations in a Small Intestinal GI Stromal Tumor-A Case Report., PMID:40353886
Early switch from run-in with targeted to immunotherapy in advanced BRAFV600-positive melanoma: final results of the randomised phase II ImmunoCobiVem trial., PMID:40345056
Advances in BRAF mutated colorectal cancer-could deoxycholic acid be the culprit?, PMID:40339670
Prevalent genetic alterations in pediatric thyroid carcinoma: Insights from an Argentinean study., PMID:40338900
New Insights into Ameloblastic Fibromas, Fibrodentinomas, and Fibro-Odontomas: Findings from an International Multicenter Study., PMID:40338415
BRAF Targeting Across Solid Tumors: Molecular Aspects and Clinical Applications., PMID:40332392
BRAF mutation in five cases of sinonasal ameloblastic tumors and their clinical course: a case report., PMID:40329362
First-line treatment of anti-EGFR monoclonal antibody cetuximab β plus FOLFIRI versus FOLFIRI alone in Chinese patients with RAS/BRAF wild-type metastatic colorectal cancer: a randomized, phase 3 trial., PMID:40328753
Differences of clinical features, prognosis and genetic mutations in Chinese patients with malignant melanoma and additional primary tumours., PMID:40317239
Design and synthesis of novel 2-S-alkylated Quinazolinones as dual BRAFV600E and EGFR inhibitors in melanoma: Mechanistic insights from apoptosis and cell cycle modulation., PMID:40311244
Search for Mutations Connected With Non-Response to Anti-EGFR Therapy in mCRC in the Morphologically Defined Regions of Primary Tumours., PMID:40302146
[Eosinophilic cells associated with BRAF mutation in borderline serous ovarian tumors]., PMID:40289428
Disease response criteria in Langerhans cell histiocytosis: a global view., PMID:40287907
Splenic Diffuse Red Pulp Small B-Cell Lymphoma with Overlapping Clinical and Immunophenotypic Features with Hairy Cell Leukaemia: A Case Report and a Review of the Literature., PMID:40282427
Prognostic significance of KRAS, NRAS, BRAF, and PIK3CA mutations in stage II/III colorectal cancer: A retrospective study and meta-analysis., PMID:40279317
Genomic mutation and Clinicopathological features of KRAS wild-type tumors in Chinese cohort with pancreatic adenocarcinoma., PMID:40274200
Exploration of risk factors for the occurrence and recurrence of papillary thyroid carcinoma with Hashimoto's thyroiditis based on next-generation sequencing., PMID:40269951
LSD1 inhibition attenuates targeted therapy-induced lineage plasticity in BRAF mutant colorectal cancer., PMID:40264166
[Treatment of metastatic melanoma: update 2025]., PMID:40262755
Molecular Alterations Influencing the Prognostic Outcome in Small Pancreatic Cancer (≤2 cm)., PMID:40262101
Associations of blood RNA biomarkers and circulating tumour cells in patients with previously untreated metastatic colorectal cancer., PMID:40259317
Unveiling the BRAF fusion structure variations through DNA and RNA sequencing., PMID:40253487
Clinical validation of droplet digital PCR assays in detecting BRAFV600-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial., PMID:40250457
Nonequilibrium hybridization-driven CRISPR/Cas adapter with extended energetic penalty for discrimination of single-nucleotide variants., PMID:40243059
Real time characterization of the MAPK pathway using native mass spectrometry., PMID:40240517
Targeting PLK1-CBX8-GPX4 axis overcomes BRAF/EGFR inhibitor resistance in BRAFV600E colorectal cancer via ferroptosis., PMID:40240371
Prevalence and Clinical Impact of BRAF p.V600E Mutation in Papillary Thyroid Carcinoma., PMID:40237893
For research use only. Not for human or drug use.
